Guardant Health rebounds as liquid biopsy test granted Medicare coverage

Aug. 02, 2022 3:52 PM ETGuardant Health, Inc. (GH)By: Dulan Lokuwithana, SA News Editor

Human Cancer Cell

luismmolina/E+ via Getty Images

  • The shares of cancer test maker Guardant Health (NASDAQ:GH) recovered from two consecutive days of losses on Tuesday after the company announced it received Medicare coverage for the Guardant Reveal molecular residual disease (MRD) test.
  • The decision of Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), means Guardant Reveal is covered in the U.S. for certain Medicare patients with stage II or III colorectal cancer (CRC).
  • Designed to detect circulating tumor DNA in the blood after surgery, Guardant Reveal can detect residual or recurring disease helping patients to benefit from adjuvant therapy.
  • The test is the first blood-based liquid biopsy test available for patients with CRC for MRD testing.
  • Read: Seeking Alpha contributor BioSci Capital Partners reiterated his Buy rating on Guardant (GH) in July, noting, among others, favorable industry trends for precision medicine diagnostics.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.